S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel

Anixa Biosciences - ANIX Stock Forecast, Price & News

$4.06
+0.16 (+4.10%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.80
$4.08
50-Day Range
$2.81
$4.08
52-Week Range
$2.30
$5.87
Volume
67,636 shs
Average Volume
60,598 shs
Market Capitalization
$123.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Anixa Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
170.9% Upside
$11.00 Price Target
Short Interest
Bearish
1.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Anixa Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

811th out of 1,135 stocks

Pharmaceutical Preparations Industry

413th out of 557 stocks

ANIX stock logo

About Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Anixa Biosciences Trading Up 4.1 %

NASDAQ:ANIX traded up $0.16 during trading on Friday, reaching $4.06. The company's stock had a trading volume of 67,636 shares, compared to its average volume of 60,598. Anixa Biosciences has a twelve month low of $2.30 and a twelve month high of $5.87. The business's fifty day moving average price is $3.35 and its 200-day moving average price is $3.10.

Anixa Biosciences (NASDAQ:ANIX - Get Rating) last posted its quarterly earnings data on Friday, June 10th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. Analysts expect that Anixa Biosciences will post -0.51 earnings per share for the current year.

Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Stock News Headlines

Anixa Biosciences, Inc. (ANIX)
Anixa Biosciences, Inc.(ANIX)
See More Headlines
Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Company Calendar

Last Earnings
6/10/2022
Today
8/14/2022
Next Earnings (Estimated)
9/07/2022
Fiscal Year End
10/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIX
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+170.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-12,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$510,000.00
Book Value
$1.16 per share

Miscellaneous

Free Float
24,621,000
Market Cap
$123.71 million
Optionable
Not Optionable
Beta
1.52














ANIX Stock - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings
or view top-rated stocks.

What is Anixa Biosciences' stock price forecast for 2022?

1 equities research analysts have issued twelve-month price objectives for Anixa Biosciences' stock. Their ANIX share price forecasts range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 170.9% from the stock's current price.
View analysts price targets for ANIX
or view top-rated stocks among Wall Street analysts.

How have ANIX shares performed in 2022?

Anixa Biosciences' stock was trading at $2.97 at the beginning of 2022. Since then, ANIX shares have increased by 36.7% and is now trading at $4.06.
View the best growth stocks for 2022 here
.

When is Anixa Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 7th 2022.
View our ANIX earnings forecast
.

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) issued its earnings results on Friday, June, 10th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01.

What other stocks do shareholders of Anixa Biosciences own?

What is Anixa Biosciences' stock symbol?

Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX."

Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include UBS Group AG (1.99%), Renaissance Technologies LLC (0.28%), Gemmer Asset Management LLC (0.11%), LPL Financial LLC (0.07%), Virtu Financial LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends
.

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anixa Biosciences' stock price today?

One share of ANIX stock can currently be purchased for approximately $4.06.

How much money does Anixa Biosciences make?

Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $123.71 million and generates $510,000.00 in revenue each year. The company earns $-12,950,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How can I contact Anixa Biosciences?

Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974.

This page (NASDAQ:ANIX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.